Publications

Success examples

Identification of Human Topoisomerase I Poison and Catalytic Inhibitors

Medaira C.

FIU Electronic Theses and Dissertations 2021, 4661.

HIV NNRTI HCV NS5B polymerase inhibitor

Success examples

Enhancing delivery of poorly water-soluble drugs by innovative amorphous solid dispersions

Jermain S. V.

The University of Texas at Austin 2019.

CCR1 antagonist

Success examples

Are we ready to design oral PROTACs®?

Jimenez D. G., Sebastiano M. R., Caron G., Ermondi G.

ADMET DMPK 2021, 9(4):243-254.

SMARCA2/4 PROTAC PTK2 PROTAC PTK2 PROTAC

Success examples

The inhibitory effect of common food spices bioactive compounds against KRAS G12C and KRAS G12D: an in-silico approach

Agosile O. O., Njoku P. C., Oduwe U., Aremu A. J., Fajobi S. J., Akachukwu S. O., Adebisi A. R., Abolaji A. O., Omirin E. S.

Research Square 2023, PREPRINT (Version 1).

KRAS switch I/II pocket inhibitor

Success examples

Development of BromoTag: A "Bump-and-Hole"-PROTAC System to Induce Potent, Rapid, and Selective Degradation of Tagged Target Proteins

Bond A. G., Craigon C., Chan K., Testa A., Karapetsas A., Fasimoye R., Macartney T., Blow J. J., Alessi D. R., Ciulli A.

J Med Chem. 2021, 64(20):15477-15502.

BET PROTAC

Success examples

Novel GLP-1 secretagogues as neuroprotective agents for retinal neurodegenerative diseases

Powell F. L., Thomas S., Martin P. M.

Invest. Ophthalmol. Vis. Sci. 2023, 64(8):1842.

GPR142 Agonist